NASDAQ · Biotechnology

First Tracks Biotherapeutics Inc (TRAX) Stock

$46.95 +2.04% NASDAQ: TRAX Healthcare

First Tracks Biotherapeutics, Inc., situated in San Diego, California, specializes in pioneering new immunology-based treatments. The firm is actively involved in the discovery and progression of therapeutics aimed at combating autoimmune and inflammatory disorders, currently advancing programs like rosnilimab, ANB033, and ANB101 through their clinical stages.

Valuation

MetricValue
Price$46.95
Market Cap$1.64B
P/E Ratio-16.71
P/B Ratio6.34
P/S Ratio0.00
EPS (TTM)$0.00
52-Week High$48.00
52-Week Low$14.72
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-30.10%
ROA-33.62%
ROCE-40.43%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.05
Current Ratio8.74

Annual Financials (USD)

Metric202320242025
Revenue$0$0$0
Operating Profit$-118.0M$-181.0M$-179.0M
Net Profit$-106.0M$-164.0M$-166.0M
EPS$-3.05$0.00$0.00
Op Margin———

Balance Sheet (USD)

Metric202320242025
Total Assets$444.0M$442.0M$331.0M
Total Liabilities$34.0M$50.0M$43.0M
Cash$36.0M$123.0M$238.0M
Borrowings$18.0M$16.0M$14.0M

Latest News

TRAX Stock Hits All-Time High — What's Driving The Super Rally? Stocktwits · Jul 10, 2026 First Tracks Biotherapeutics Announces Participation in Upcoming Investor Conferences GlobeNewswire · May 21, 2026 How The Grupo Traxión (BMV:TRAXION A) Story Is Shifting With Cautious New Analyst Targets Simply Wall St. · May 15, 2026 First Tracks Biotherapeutics Announces First Quarter 2026 Financial Results and Provides Business Update GlobeNewswire · May 14, 2026 Anaptys Announces First Quarter 2026 Financial Results and Provides Business Update GlobeNewswire · May 12, 2026

Cash Flow (USD)

Metric202320242025
Operating Cash Flow$-93.0M$-126.0M$-143.0M
Investing Cash Flow$144.0M$95.0M$228.0M
Financing Cash Flow$0$0$30.0M
Net Cash Flow$-35.0M$87.0M$115.0M
Free Cash Flow$-94.0M$-126.0M$-143.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.17
EV / EBITDA-13.77
FCF Yield-4.64%
Quick Ratio8.74
Interest Coverage0.00
Return 1Y—
Return 3Y—
Return 5Y—

Ownership

Insiders Held6.60%
Institutions Held52.43%
Institutions Float Held56.13%
Institutional HolderSharesReport Date
Financial Enhancement Group LLC74,4502026-06-30
Moody Aldrich Partners LLC54,3162026-06-30
Tema Etfs LLC 30,9072026-06-30
Y Intercept (Hong Kong) Ltd28,0842026-06-30
MassMutual Private Wealth & Trust, FSB212026-06-30

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPLApple Inc. $313.33 +0.29% 37.72 $4.60T 0.34%
MSFTMicrosoft Corporation $499.99 +0.03% 22.95 $3.71T 0.94%
GOOGLAlphabet Inc. $354.30 -0.96% 27.68 $4.29T 0.23%
AMZNAmazon.com, Inc. $274.48 +0.82% 28.76 $2.95T 0.00%
METAMeta Platforms, Inc. $592.10 +0.37% 21.47 $1.51T 0.35%

About First Tracks Biotherapeutics Inc

First Tracks Biotherapeutics, Inc., situated in San Diego, California, specializes in pioneering new immunology-based treatments. The firm is actively involved in the discovery and progression of therapeutics aimed at combating autoimmune and inflammatory disorders, currently advancing programs like rosnilimab, ANB033, and ANB101 through their clinical stages.

First Tracks Biotherapeutics Inc is led by CEO Daniel R. Faga, employs 104 people, headquartered in US, publicly traded since 2026.

First Tracks Biotherapeutics Inc (TRAX) stock trades at $46.95 with a market capitalization of $1.64B. The stock is valued at a price-to-earnings (P/E) ratio of -16.71, price-to-book of 6.34, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $14.72 and $48.00, and currently trades 2.2% below its 52-week high.

On profitability, First Tracks Biotherapeutics Inc generates a return on equity (ROE) of -30.10%, return on capital employed of -40.43%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: www.firsttracksbio.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides